OpenEvidence deserves genuine credit for making differences in evidence strength visible to clinicians rather than leaving every citation looking equally authoritative. It is worth being equally direct, however, about what EvidenceGrade does not tell a UK-based clinician, given the platform's predominantly American clinical orientation and its positioning around US clinicians and predominantly US-sourced peer-reviewed literature.
The additional questions a UK clinician actually needs answered
Is the medicine licensed for this specific indication in the UK. Does NICE, or the relevant devolved-nation equivalent, actually recommend it. Is it realistically available through the NHS pathway a given patient would go through. Does the current SmPC alter recommended dosing or monitoring relative to what a US trial protocol assumed. And is the referral structure genuinely organised the same way in the UK as it was in the healthcare system the underlying evidence was generated within.
Why evidence strength and national applicability are genuinely separate questions
A high EvidenceGrade tells a clinician the underlying literature is strong. It says nothing about any of the five UK-specific questions above, because those questions depend on regulatory, formulary and healthcare-system facts entirely external to the strength of the clinical trial evidence itself.
Where iatroX is positioned differently
iatroX was founded by a UK-based practising clinician, and its clinical decision-support functionality, Ask iatroX, is UKCA-marked and MHRA-registered as a Class I medical device for that specific use. It is grounded in UK clinical guidelines alongside relevant international evidence, developed directly around the retrieval problems real NHS clinicians encounter in day-to-day practice.
iatroX's evidence principle, stated plainly
The working approach prefers authoritative UK guideline synthesis and the strongest appropriate underlying evidence together, favours high-quality systematic reviews and meta-analyses where they genuinely apply to the question, and is willing to escalate towards newer individual studies specifically where UK guidance may not yet have caught up with recently published evidence.
A balanced conclusion worth stating directly
OpenEvidence is a genuinely valuable tool for rapid synthesis of international evidence, and EvidenceGrade is a real, useful advance in making that evidence's underlying strength visible. iatroX is the more natural fit specifically for UK-contextualised clinical decisions, where licensing, guidance and pathway questions sit alongside evidence strength as equally necessary information. Neither tool, used well, should replace a clinician's own judgement or a direct look at primary evidence for genuinely high-stakes decisions.
Why this gap will not close simply by improving evidence grading
It is worth being direct about a structural point: no amount of further refinement to EvidenceGrade's underlying methodology closes the specific gap described above, because the gap is not a grading-quality problem at all. Evidence strength and jurisdictional applicability are genuinely independent dimensions, and a platform built primarily around US clinical workflows and predominantly US-oriented literature would need a separate, deliberate UK-specific layer, licensing status, NICE concordance, NHS pathway mapping, to close it, regardless of how sophisticated its evidence grading eventually becomes. This is precisely the layer a UK-founded platform is positioned to build in from the outset rather than add on afterwards.
A concrete illustration worth holding in mind
A UK GP asking about a newer treatment option might receive a technically accurate, well-graded answer describing strong US trial evidence, while the actual, practically useful answer for that GP's next action depends on whether NICE has appraised the treatment, whether it is available on the NHS formulary locally, and whether the referral pathway assumed by the trial protocol has any UK equivalent at all. All three of these can be true or false independently of how strong the underlying trial evidence is.